ConductScience.org, home

Gene · 10

NAT2: N-acetyltransferase 2

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. NAT2: N-acetyltransferase 2. Genes, record 10. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10

On this page

Gene

Symbol
NAT2
HGNC
Name
N-acetyltransferase 2
HGNC
NCBI Gene ID
10
NCBI Gene
HGNC ID
HGNC:7646
HGNC
Ensembl
ENSG00000156006
NCBI Gene
Aliases
AAC2, NAT-2, PNAT
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P11245Arylamine N-acetyltransferase 22901Ensembl, GeneID, HGNC

Source UniProt

Patents11

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1454876P11245Espacenet
EP 4641201 A22025-10-292865P11245Espacenet
JP 2025517969 A2025-06-122865P11245Espacenet
US 11446398 B22022-09-2054890P11245Espacenet
US 11400116 B22022-08-021P11245Espacenet
JP 2022524081 A2022-04-27157861P11245Espacenet
US 11078247 B22021-08-037276P11245Espacenet
JP 2019054813 A2019-04-11235311P11245Espacenet
JP 2017121241 A2017-07-13235311P11245Espacenet
JP 2015516143 A2015-06-08235311P11245Espacenet

1 to 10 of 11

See all 11 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants1,535

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleNAT2 papersNewest fiscal year
P20GM113226Hepatobiology and Toxicology COBRE322025
T32ES011564UOFL ENVIRONMENTAL HEALTH SCIENCES TRAINING PROGRAM292025
P42ES023716Environmental Exposure and Cardiometabolic Disease232025
UM1AI068634Statistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG)152025
UM1AI068636Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections152025
UM1AI106701AIDS Clinical Trial Group Laboratory Center152025
P30CA016672Cancer Center Support Grant92025
R01AI077505Pharmacogenomics of HIV Therapy92025
P50AA024337The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ Injury82025
UM1AI068632IMPAACT Leadership Group82025

1 to 10 of 1,535Source NIH's project files

See all 1,535 nih grants

Papers3,552

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Analysis of NAT2 coding variants, combined genotypes, and haplotypes in prostate cancer susceptibility: a case-control study in an Iraqi Arab population.Mol Biol Rep202642801388PubTator, text miningPubMed
Genetic Variants at the NAT2 and HLA-DOA are Associated With Anti-Tuberculosis Drug-Induced Liver Injury Susceptibility and Clinical Manifestations in Western Chinese Populations.Immun Inflamm Dis202642742466PubTator, text miningPubMed
Regimen-Specific Population Pharmacokinetics of Isoniazid with and Without Rifamycin: A Bayesian Modeling Analysis of 6H, 3HR, and 3H2P2 Regimens.Pharmaceutics202642654054PubTator, text miningPubMed
Characterization of NAT2 Using Long-Read Sequencing: Allele, Diplotype, and Phenotype Call Accuracy Compared to Other Testing Strategies.Clin Pharmacol Ther202642572153PubTator, text miningPubMed
Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel.Clin Pharmacol Ther202642538601PubTator, text miningPubMed
Impact of NAT2 acetylation phenotype on toxicity in tuberculosis therapy: a systematic review and meta-analysis.Pharmacogenomics202642531284PubTator, text miningPubMed
Genetic Landscape of NAT2 in the Moroccan Population: Implications for Isoniazid Pharmacogenetics in Tuberculosis.Clin Transl Sci202642504089PubTator, text miningPubMed
Association of Selected Genetic Variants in CYP1A1, CYP2D6, NAT1 and NAT2 with Endometrial Cancer Risk: A Preliminary Case-Control Study.Int J Mol Sci202642450020PubTator, text miningPubMed
Correction to "Study on Genotyping Polymorphism and Sequencing of N-Acetyltransferase 2 (NAT2) Among Al-Ahsa Population".Biomed Res Int202642444030PubTator, text miningPubMed
Toxicity assessment of three emerging bisphenols (BPA, BPAP and BPC) and their binary mixtures in an advanced in vitro 3D HepG2 cell model.Chem Biol Interact202642385970PubTator, text miningPubMed

1 to 10 of 3,552

See all 3,552 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/10

GET https://conductscience.org/api/genes/v1/10/patents